Search
Cupric Chloride
go.drugbank.com/drugs/DB09131ApprovedCupric chloride, for injection, is a sterile, nonpyrogenic solution intended for use as an additive to solutions for Total Parenteral Nutrition (TPN).
Mixtures: ADDAMEL N, ADDAMEL NRozanolixizumab
go.drugbank.com/drugs/DB14919ApprovedInvestigational[L47122] It was granted orphan drug designation by the FDA in 2019, by the European Medicines Agency (EMA) in April 2020, and by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) in November … Rozanolixizumab-noli is available under the brand name RYSTIGGO and was developed by UCB.
Sarafloxacin
go.drugbank.com/drugs/DB11491ApprovedVet approvedWithdrawnSarafloxacin is a quinolone antibiotic drug, which was discontinued by its manufacturer, Abbott Laboratories, before receiving approval for use in the US or Canada.
Silodosin
go.drugbank.com/drugs/DB06207ApprovedInvestigational[A231159] Silodosin was first approved by the FDA in October 2008 [A231159] and it is also approved in Europe and Canada. … [A231159] Silodosin works by binding to α<sub>1A</sub>-adrenoceptors with high affinity and relaxing the lower urinary tract, thereby improving urinary symptoms and alleviating bladder outlet obstruction
Aprobarbital
go.drugbank.com/drugs/DB01352ExperimentalIllicitAprobarbital is a barbiturate derivative synthesized in the 1920s by Ernst Preiswerk. It was determined that the substance was capable of demonstrating sedative, hypnotic, and anticonvulsant effects.
Linifanib
go.drugbank.com/drugs/DB06080Investigationalthat supply the tumor with oxygen and nutrients and by inhibiting key angiogenic signaling pathways. … Linifanib (ABT-869) is a small molecule vascular endothelial growth factor (VEGF) receptor-based kinase inhibitor that is designed to suppress tumor growth by preventing the formation of new blood vessels
Synonyms: N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N1-(2-fluoro-5-methylphenyl) urea, UREA, N-(4-(3-AMINO-1H-INDAZOL-4-YL)PHENYL)-N'-(2-FLUORO-5-METHYLPHENYL)-Actelion-1
go.drugbank.com/drugs/DB05367ExperimentalActelion-1 is a tissue-targeting Endothelin Receptor Antagonist that has been discovered by Actelion Pharmaceuticals.
Beractant
go.drugbank.com/drugs/DB06761ApprovedConsidered a natural source of surfactant as it is made from bovine lung extract, beractant contains a mixture of phospholipids, neutral lipids, fatty acids, and surfactant-associated proteins such as
Riluzole
go.drugbank.com/drugs/DB00740ApprovedInvestigationalRiluzole is marketed as Rilutek by Sanofi.
Pazopanib
go.drugbank.com/drugs/DB06589ApprovedInvestigationalIt is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.